Evaluation of Fluid Infusion With LifeFlow for Patients With Suspected Septic Shock
Sepsis, Volume Assessment
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
- Adult ED patients ≥ 18 years of age
Patients with hypotension (Systolic Blood Pressure (SBP) < 90) mmHg or Mean Arterial Pressure (MAP) < 65 mmHg) and at least one of the following:
- Temperature > 101 F (38.3 C) or < 96.8 F (36.0 C)
- Respiratory Rate (RR) > 22 bpm
- Heart Rate (HR) > 90/min
- Patients who will be determined by treating emergency physician to receive rapid fluid bolus for hypotension
- Patients with adequate cardiac windows
- EF is 35% or greater
- No increased number of B lines per rib interspace (3 or more) in multiple locations on lung ultrasound
Exclusion Criteria:
- Heart failure by history or Ejection fraction (EF) < 35 percent on pre-enrollment Point of care (POC) Echocardiogram
- History of End stage Renal disease
- History of End stage lung disease
- Lymphocyte count < 50mm/m3 or Absolute Neutrophil Count < 500
- Transferred from another facility
- Requirement for immediate surgery
- Patients with 14 Gauge catheters or larger
- Concurrently on vasopressors or inotrope therapy
- Patients or legally acceptable representatives unable to provide consent
- Non-sepsis related primary diagnosis including: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, active gastrointestinal hemorrhage, seizure, drug overdose, burn or trauma, myocardial infarction or active hemorrhage
- Incarcerated patients
- Requirement for immediate surgery
- Known pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control
LifeFlow group
After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.